| Anjum S Owaisi, MD | |
|
396 Remington Blvd, Suite 330, Bolingbrook, IL 60440-4302 | |
| (888) 220-6432 | |
| (630) 654-4253 |
| Full Name | Anjum S Owaisi |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 23 Years |
| Location | 396 Remington Blvd, Bolingbrook, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942341409 | NPI | - | NPPES |
| 036-110632 | Other | IL | MEDICAL LICENSE NUMBER |
| 036110632 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 036-110632 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Bolingbrook Hospital | Bolingbrook, IL | Hospital |
| Adventist Hinsdale Hospital | Hinsdale, IL | Hospital |
| Edward Hospital | Naperville, IL | Hospital |
| Elmhurst Memorial Hospital | Elmhurst, IL | Hospital |
| Adventist Glenoaks | Glendale heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metro Infectious Disease Consultants Llc | 3072425784 | 297 |
News Archive
Hyperion Therapeutics, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
Michael Yarborough, a 58-year-old business owner from Waxahachie, Texas, was fortunate. A routine check-up three years ago revealed prostate cancer, but a side effect of his successful surgery was "driving him nuts."
HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL Mites in order to support the optimal dose in terms of clinical efficacy and safety.
Racial Disparities In The Outcomes Of Communication On Medical Care Received Near Death Black patients receive more life prolonging measures and less comfort-directed care at the end of life (EOL) than white patients, such as increased rates of resuscitation, intensive care unit hospitalization, and feeding tube use at the EOL, write the authors of this study that examined whether differences in patient-physician communication contribute to these differences.
› Verified 8 days ago
| Entity Name | Metro Infectious Disease Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235125717 PECOS PAC ID: 3072425784 Enrollment ID: O20031103000274 |
News Archive
Hyperion Therapeutics, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
Michael Yarborough, a 58-year-old business owner from Waxahachie, Texas, was fortunate. A routine check-up three years ago revealed prostate cancer, but a side effect of his successful surgery was "driving him nuts."
HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL Mites in order to support the optimal dose in terms of clinical efficacy and safety.
Racial Disparities In The Outcomes Of Communication On Medical Care Received Near Death Black patients receive more life prolonging measures and less comfort-directed care at the end of life (EOL) than white patients, such as increased rates of resuscitation, intensive care unit hospitalization, and feeding tube use at the EOL, write the authors of this study that examined whether differences in patient-physician communication contribute to these differences.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anjum S Owaisi, MD 901 Mcclintock Dr, Suite 202, Burr Ridge, IL 60527-0872 Ph: (888) 220-6432 | Anjum S Owaisi, MD 396 Remington Blvd, Suite 330, Bolingbrook, IL 60440-4302 Ph: (888) 220-6432 |
News Archive
Hyperion Therapeutics, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.
Teleflex Incorporated today announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the company's ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
Michael Yarborough, a 58-year-old business owner from Waxahachie, Texas, was fortunate. A routine check-up three years ago revealed prostate cancer, but a side effect of his successful surgery was "driving him nuts."
HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL Mites in order to support the optimal dose in terms of clinical efficacy and safety.
Racial Disparities In The Outcomes Of Communication On Medical Care Received Near Death Black patients receive more life prolonging measures and less comfort-directed care at the end of life (EOL) than white patients, such as increased rates of resuscitation, intensive care unit hospitalization, and feeding tube use at the EOL, write the authors of this study that examined whether differences in patient-physician communication contribute to these differences.
› Verified 8 days ago
Abdus Samad Soudagar, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 396 Remington Blvd, 260, Bolingbrook, IL 60440 Phone: 630-312-2590 | |
Fatima Saifuddin, M.D Infectious Disease Medicare: Medicare Enrolled Practice Location: 396 Remington Blvd Ste 380, Bolingbrook, IL 60440 Phone: 630-861-6278 | |
Melissa Marie Kelly, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 Remington Blvd, Suite 200 Attn: Aim, Bolingbrook, IL 60440 Phone: 630-312-7755 | |
Dr. Stephen Lee, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 Remington Blvd, Suite 200, Bolingbrook, IL 60440 Phone: 630-312-7755 Fax: 630-856-9933 | |
Riddhi Pakrasi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 130 N Weber Rd, Suite 100, Bolingbrook, IL 60440 Phone: 630-646-5777 Fax: 630-646-5729 | |
Valentina Macrinici, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 420 S Schmidt Rd, Suite 230, Bolingbrook, IL 60440 Phone: 630-312-2000 | |
Dr. Huma Q. Rohail, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 396 Remington Blvd Ste 140, Bolingbrook, IL 60440 Phone: 630-495-9356 Fax: 630-495-9357 |